Revoking the privilege: targeting HER2 in the central nervous system

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Targeted cancer therapies aim to exploit differences between tumor and normal cells.
• The epidermal growth factor receptor (EGFR) family is a key target in cancer therapy.
• Resistance mechanisms and limitations like the blood-brain barrier (BBB) necessitate novel therapeutic strategies.

Discussion:

• Trastuzumab, an anti-Her2 antibody, improves survival in breast cancer but lacks central nervous system (CNS) activity due to the BBB.
• Emanuel et al. report a novel tyrosine kinase inhibitor targeting Her2/neu that effectively penetrates the BBB.
• This development offers a potential new avenue for treating CNS metastases and primary brain tumors.

Key Insights:

• Development of targeted therapies that overcome the BBB is crucial for CNS cancer treatment.
• Her2/neu inhibitors crossing the BBB could overcome resistance mechanisms and improve patient outcomes.
• This research highlights the potential for repurposing EGFR-family targeting strategies for brain malignancies.

Outlook:

• Further research into BBB-penetrant tyrosine kinase inhibitors is warranted.
• Clinical trials are needed to evaluate the efficacy of these agents in CNS cancers.
• Improved treatment strategies for gliomas, medulloblastoma, and breast cancer brain metastases may emerge.